Etoposide Phosphate
FDA-approved product (injectable, injection), marketed as Etopophos Preservative Free.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Lung cancer
- Lung neoplasm
- Neoplasm
- Small cell carcinoma
- Small cell lung carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Podophyllotoxin derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Etoposide Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
NCT00499616 · start 2007-10-08
Registered record
- Registry ID
- NCT00499616
- Conditions
- Neuroblastoma
- Interventions
- carboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide; topotecan hydrochloride; Isotretinoin; Surgery; Filgrastim
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-10-08
- Completion
- 2021-06-30
- Enrolment
- 464
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeuroblastomaInterventioncarboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide +4 morePhasePhase 3Registry statusCompletedPhase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
NCT00504751 · start 2007-05
Registered record
- Registry ID
- NCT00504751
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- bortezomib, dexamethasone, ifosfamide; mesna, cisplatin, etoposide, rituximab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-05
- Completion
- 2012-02-17
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-Hodgkin's LymphomaInterventionbortezomib, dexamethasone, ifosfamide; mesna, cisplatin, etoposide, rituximabPhasePhase 2Registry statusCompletedCombination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
NCT00526318 · start 2007-01
Registered record
- Registry ID
- NCT00526318
- Conditions
- Neuroblastoma
- Interventions
- filgrastim; carboplatin; cisplatin; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; isotretinoin; melphalan; topotecan hydrochloride; vincristine sulfate; vindesine; autologous hematopoietic stem cell transplantation; iobenguane I 131; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2007-01
- Completion
- Not recorded
- Enrolment
- 360
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeuroblastomaInterventionfilgrastim; carboplatin; cisplatin; cyclophosphamide +12 morePhaseNot applicableRegistry statusUnknownUARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
NCT00574080 · start 2006-07
Registered record
- Registry ID
- NCT00574080
- Conditions
- Multiple Myeloma
- Interventions
- Interim/Maintenance Dexamethasone; Induction/Consolidation Dexamethasone; Induction/Consolidation Cisplatin; Induction/Consolidation Adriamycin; InductionConsolidation Cyclophosphamide; Induction/Consolidation Etoposide; Induction Pegfilgrastim; Transplant 1 Dexamethasone; Transplant 1 Cisplatin; Transplant 1 Adriamycin; Transplant 1 Cyclophosphamide; Transplant 1 Etoposide; Transplant 1 Melphalan; Transplant 1 and 2 Pegfilgrastim; Autologous Peripheral Blood Stem Cell Transplant (ASCT); Transplant 2 Carmustine; Transplant 2 Etoposide; Transplant 2 Cytarabine; Transplant 2 Melphalan; Transplant 2 Dexamethasone; Transplant 1 and 2 Bortezomib; Transplant 1 and 2 Thalidomide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2006-07
- Completion
- 2011-03
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple MyelomaInterventionInterim/Maintenance Dexamethasone; Induction/Consolidation Dexamethasone; Induction/Consolidation Cisplatin; Induction/Consolidation Adriamycin +18 morePhasePhase 3Registry statusTerminatedPost-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
NCT00477035 · start 2006-05
Registered record
- Registry ID
- NCT00477035
- Conditions
- Leukemia; Multiple Myeloma
- Interventions
- CIK cells; etoposide; bcnu; cyclophosphamide; gemcitabine; vinorelbine; melphalan
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2011-03
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia; Multiple MyelomaInterventionCIK cells; etoposide; bcnu; cyclophosphamide +3 morePhasePhase 1Registry statusCompletedA Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
NCT00315705 · start 2006-03
Registered record
- Registry ID
- NCT00315705
- Conditions
- Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Relapsed Leukemia
- Interventions
- clofarabine; Etoposide; Cyclophosphamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2006-03
- Completion
- 2010-05
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Relapsed LeukemiaInterventionclofarabine; Etoposide; CyclophosphamidePhasePhase 1 / Phase 2Registry statusCompletedCombination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
NCT00392886 · start 2004-03
Registered record
- Registry ID
- NCT00392886
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carboplatin; cisplatin; cyclophosphamide; etoposide; methotrexate; temozolomide; thiotepa; vincristine sulfate; autologous bone marrow transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2004-03
- Completion
- Not recorded
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBrain and Central Nervous System TumorsInterventioncarboplatin; cisplatin; cyclophosphamide; etoposide +8 morePhasePhase 3Registry statusUnknownAutologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
NCT00505921 · start 2003-03
Registered record
- Registry ID
- NCT00505921
- Conditions
- Lymphoma
- Interventions
- Campath-1H; G-CSF; GM-CSF; BCNU; Stem Cell Transplant; Preparative Regimen for Allogenic Stem Cell Transplantation; Cytarabine; Etoposide; Melphalan; Campath; Fludarabine; Cyclophosphamide; Low dose total body irradiation
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2003-03
- Completion
- 2009-11
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionCampath-1H; G-CSF; GM-CSF; BCNU +9 morePhasePhase 2Registry statusTerminatedStem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
NCT00043979 · start 2002-09-19
Registered record
- Registry ID
- NCT00043979
- Conditions
- Sarcoma
- Interventions
- F-18 Fluorodeoxyglucose; therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine; doxorubicin hydrochloride; etoposide; fludarabine phosphate; melphalan; prednisone; sirolimus; tacrolimus; vincristine sulfate; peripheral blood stem cell transplantation; Filgrastim; Peripheral Blood Stem Cell donation
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-09-19
- Completion
- 2011-12-14
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSarcomaInterventionF-18 Fluorodeoxyglucose; therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine +11 morePhasePhase 2Registry statusCompletedImmunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
NCT00366275 · start 2002-01
Registered record
- Registry ID
- NCT00366275
- Conditions
- Follicular Lymphoma
- Interventions
- Immunochemotherapy, in vivo purging and autrotransplant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-01
- Completion
- 2007-09
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFollicular LymphomaInterventionImmunochemotherapy, in vivo purging and autrotransplantPhasePhase 2Registry statusCompletedChemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
NCT00006184 · start 2001-02-08
Registered record
- Registry ID
- NCT00006184
- Conditions
- Multiple Myeloma
- Interventions
- Myeloma Immunoglobulin Idiotype Vaccine; Bortezomib; Cyclophosphamide; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine Sulfate; Methotrexate; GMCSF (granulocyte macrophage colony stimulating factor); GCSF (granulocyte colony stimulating factor)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2001-02-08
- Completion
- 2008-01-12
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple MyelomaInterventionMyeloma Immunoglobulin Idiotype Vaccine; Bortezomib; Cyclophosphamide; Cyclosporine +8 morePhasePhase 2Registry statusCompletedFilgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
NCT00005985 · start 2000-08
Registered record
- Registry ID
- NCT00005985
- Conditions
- Lymphoma
- Interventions
- filgrastim; carmustine; cyclophosphamide; cytarabine; dexamethasone; etoposide; mitoxantrone hydrochloride; peripheral blood stem cell transplantation; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2000-08
- Completion
- 2007-02
- Enrolment
- 213
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionfilgrastim; carmustine; cyclophosphamide; cytarabine +5 morePhasePhase 2Registry statusCompletedStudy of Etoposide in Breast Cancer Patients
NCT00026949 · start 1999-08
Registered record
- Registry ID
- NCT00026949
- Conditions
- Breast Cancer
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1999-08
- Completion
- 2004-08
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionNot recordedPhaseNot recordedRegistry statusCompletedCombination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
NCT00003621 · start 1999-02
Registered record
- Registry ID
- NCT00003621
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carmustine; cisplatin; etoposide; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-02
- Completion
- 2005-07
- Enrolment
- 29
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBrain and Central Nervous System TumorsInterventioncarmustine; cisplatin; etoposide; radiation therapyPhasePhase 2Registry statusCompletedCombination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
NCT00049439 · start 1998-03
Registered record
- Registry ID
- NCT00049439
- Conditions
- Lymphoma
- Interventions
- filgrastim; cyclophosphamide; etoposide; lomustine; procarbazine hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1998-03
- Completion
- 2008-02
- Enrolment
- 54
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionfilgrastim; cyclophosphamide; etoposide; lomustine +1 morePhasePhase 2Registry statusCompleted